Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of COVID-19 Pneumonia on Pulmonary Physiology, Health-related Quality of Life and Benefit of a Rehabilitation Program (COVISQAR)

NCT04881214 is registered in ClinicalTrials.gov with University Hospital, Geneva as lead sponsor.

NCT NCT04881214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04881214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of COVID-19 Pneumonia on Pulmonary Physiology, Health-related Quality of Life and Benefit of a Rehabilitation Program (COVISQAR)
Lead sponsor
University Hospital, Geneva
Phase
Not applicable
Overall status
Unknown status
Start date
July 1, 2020
Completion date
June 30, 2023
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic thromboembolic pulmonary hypertension, covid19 pneumonia, myopathy, restrictive lung disease